Arcutis Biotherapeutics (ARQT) Finished Goods (2022 - 2026)
Arcutis Biotherapeutics (ARQT) posted quarterly Finished Goods of $14.7 million for Q1 2026, up 77.45% year-over-year from $8.3 million in Q1 2025, and up 16.93% quarter-over-quarter from $12.6 million in Q4 2025.
Arcutis Biotherapeutics (ARQT) Finished Goods (2022 - 2026) Analysis & Trends
Arcutis Biotherapeutics' Finished Goods history runs 5 years deep, the most recent figure standing at $14.7 million for Q1 2026.
- In Q1 2026, Finished Goods rose 77.45% year-over-year to $14.7 million; the TTM figure through Mar 2026 stood at $14.7 million (up 77.45% YoY), while the FY2025 annual figure was $12.6 million, up 30.2% from the prior year.
- Finished Goods for Q1 2026 stood at $14.7 million, up from $12.6 million in the prior quarter.
- The five-year high for Finished Goods was $14.7 million in Q1 2026, with the low at $698000.0 in Q3 2022.
- The 5-year median for Finished Goods is $5.8 million (2024), against an average of $6.2 million.
- The sharpest annual moves came in 2024 and 2025: Finished Goods jumped 257.51% in 2024, then surged 30.2% in 2025.
- Arcutis Biotherapeutics' Finished Goods stood at $1.5 million in 2022, then jumped by 84.73% to $2.7 million in 2023, then surged by 257.51% to $9.6 million in 2024, then jumped by 30.2% to $12.6 million in 2025, then advanced by 16.93% to $14.7 million in 2026.
- Business Quant data shows ARQT's Finished Goods at $14.7 million in Q1 2026, $12.6 million in Q4 2025, and $11.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Arcutis Biotherapeutics | 3.29 Bn | 3.05 Bn | 118.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 14.17 Mn |
| Mar 31, 2026 | 14.68 Mn |
| Dec 31, 2025 | 12.55 Mn |
| Sep 30, 2025 | 11.58 Mn |
| Jun 30, 2025 | 7.87 Mn |
| Mar 31, 2025 | 8.27 Mn |
| Dec 31, 2024 | 9.64 Mn |
| Sep 30, 2024 | 8.14 Mn |
| Jun 30, 2024 | 5.82 Mn |
| Mar 31, 2024 | 2.74 Mn |
| Dec 31, 2023 | 2.70 Mn |
| Sep 30, 2023 | 2.35 Mn |
| Jun 30, 2023 | 1.93 Mn |
| Mar 31, 2023 | 1.91 Mn |
| Dec 31, 2022 | 1.46 Mn |
| Sep 30, 2022 | 698,000.00 |